催化剂制药 CPRX 深 沪
等待开盘 05-12 09:30:00 美东时间
31.15
-0.010
-0.03%
华盛通- 最 高31.29
- 今 开31.15
- 成交量 365.76万股
- 最 低 30.17
- 昨 收 31.16
- 总市值 320.85万
- 52周最高 32.56
- 市盈率 静 85.04
- 换手率 3551.05%
- 52周最低 19.05
- 委 比 -12.23%
- 总股本 0.00亿
- 历史最高 32.56
- 量 比 0.81
- 振 幅 3.59%
- 历史最低 0.37
- 每 手 1
- 风险率 2.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Catalyst Pharmaceuticals Q1 Sales $149.390M Beat $148.174M Estimate.
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly sales of $149.390 million which beat the analyst consensus estimate of $148.174 million by 0.82 percent. This is a 5.63 percent increase over sales of $141.421
11分钟前
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Stephens & Co. Downgrades Catalyst Pharmaceuticals to Equal-Weight
Stephens & Co. analyst Sudan Loganathan downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) from Overweight to Equal-Weight.
05-07 21:40
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Capricor Therapeutics announced positive four-year safety and efficacy results for Deramiocel in treating Duchenne muscular dystrophy (DMD), showing preservation of cardiac function, slowed disease progression, and a favorable safety profile. Results were presented at PPMD’s 2025 Annual Conference.
2025-06-20 13:25
Canterbury Park Holding Corporation Announces Quarterly Cash Dividend
Canterbury Park Holding Corporation announced a quarterly cash dividend of $0.07 per share, equivalent to $0.28 annually, to be paid on July 14, 2025 to stockholders of record on June 30, 2025. The company owns and operates Canterbury Park Racetrack and Casino in Shakopee, Minnesota, offering live racing, casino games, and year-round wagering on simulcast horse racing. It also pursues mixed-use development opportunities on underutilized land around the Racetrack.
2025-06-13 20:00
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
Dr. Gary Ingenito is retiring from Catalyst after a successful career, and Dr. William T. Andrews has been appointed as the new Chief Medical Officer. Andrew brings extensive experience in biopharmaceuticals, particularly in rare diseases.
2025-06-02 12:03
Catalyst Pharma's FIRDAPSE Approved in Japan for Rare Autoimmune Disorder Lambert-Eaton Myasthenic Syndrome ("LEMS")
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with
2024-09-24 18:08
